Amgen

Open: 224.21 Close: 225.29 Change: 1.08

Stop reading the whole internet to decide if you want to invest in Amgen.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, Horizon, drug, patent, Inc, Therapeutics, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen Inc. (AMGN) stock has fallen 4.31% in a week. Federal Trade Commission (FTC) said Tuesday it will sue to stop Amgen $27.8 billion acquisition of Horizon Therapeutics. FTC said the deal would allow Amgen to entrench the monopoly positions.

Today's News

Amgen Inc. sought to collect millions of millions of dollars in damages in a lawsuit dating back nine years. Amgen, TScan Therapeutics set Crohns Disease Collaboration May. Amgen would be able to offer rebates on its existing medicines to pressure insurers and pharmacy benefit managers into favoring the two Horizon products. The agency said the deal would allow Amgen to entrench the monopoly positions Amgen facing lawsuit over $10.7 billion in irs taxes and penalties. Amgen Inc. (AMGN) latest stock news & headlines - yahoo finance. amgen inc. (amgn) Latest Stock News & Headlines. U.S. Supreme Court rules against Amgen Inc in bid to revive patents on its cholesterol-lowering drug Repatha. Conservative Justice Neil Gorsuch wrote for the court that we agree with the lower courts Amgen Inc. environmental senior manager job with amgen. Be part of Amgens newest and most advanced drug substance manufacturing plant. Amgen (NASDAQ:AMGN) Loses Patent Battle to Sanofi, Regeneron in patent infringement case. U.S. Supreme Court ruled against Amgen in patent case between Amgen and Sanofi. Amgen settles J&J patent lawsuit over drug similar to blockbuster Stelara. U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents. FTC faces uphill battle in its fight to block Amgens $27.8 billion takeover of Horizon Therapeutics. FTC sues to block Amgens $27.8 billion purchase of Horizon Therapeutics. FTC is attempting to stop the sale out of fears it will give the company too much power over rare disease treatments. Jefferies managing director Michael Yee expects Amgens Horizon deal will go through despite FTC block. Amgen, Inc. (AMGN) stock has fallen 4.31% in a week. The Supreme Court has unanimously voted in favour of Sanofi by upholding a past legal verdict that invalidated Amgens two patents. Amgen is a leader in biotechnology-based human therapeutics. Federal Trade Commission announced Tuesday that it will oppose the Amgen-Horizon deal on grounds it will stifle innovation and the development of new drugs. FTC also said the FTCs case against Amgen and Horizon could slam the proverbial brakes. FTC sues to block Amgen s $27.8 billion   acquisition   of Horizon Therapeutics. FTC argued the deal would allow Amgen to build monopolies around two of Horizons drugs. Federal Trade Commission (FTC) said Tuesday it will sue to stop Amgen $27.8 billion acquisition of Horizon Therapeutics. FTC said in the complaint that Amgen would be able to leverage its position with insurance companies and pharmacy benefit managers wanting access to its blockbuster drugs.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, Horizon, drug, patent, Inc, Therapeutics, and the most common words in the summary are: amgen, stock, best, market, horizon, news, amgens, . One of the sentences in the summary was: FTC said the deal would allow Amgen to entrench the monopoly positions.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #best #market #horizon #news #amgens.